Medulloblastoma of the adult: results from a multicenter retrospective study by AINO (Italian Association of Neuro-Oncology) and SIN (Italian Society of Neurology)

go back to reference Smoll NR, Drummond KJ et al (2012) The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci 19(11):1541–1544CrossRef Smoll NR, Drummond KJ et al (2012) The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci 19(11):1541–1544CrossRef

go back to reference Silvani A, Gaviani P, Lamperti E, Botturi A, DiMeco F, Franzini A, Ferroli P, Fariselli L, Milanesi I, Erbetta A, Pollo B, Salmaggi A (2012) Adult medulloblastoma: multiagent chemotherapy with cisplatinum and etoposide: a single institutional experience. J Neuro-Oncol 106(3):595–600CrossRef Silvani A, Gaviani P, Lamperti E, Botturi A, DiMeco F, Franzini A, Ferroli P, Fariselli L, Milanesi I, Erbetta A, Pollo B, Salmaggi A (2012) Adult medulloblastoma: multiagent chemotherapy with cisplatinum and etoposide: a single institutional experience. J Neuro-Oncol 106(3):595–600CrossRef

go back to reference Brandes AA, Franceschi E, Tosoni A, Blatt V, Ermani M (2007) Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer 110(9):2035–2041CrossRef Brandes AA, Franceschi E, Tosoni A, Blatt V, Ermani M (2007) Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer 110(9):2035–2041CrossRef

go back to reference Buglione M, Ghirardelli P, Triggiani L, Pedretti S, Pasinetti N, de Bari B, Tonoli S, Borghetti P, Spiazzi L, Magrini SM (2015) Radiotherapy for adult medulloblastoma: long term result from a single institution. A review of prognostic factors and why we do need a multi-institutional cooperative program. Rep Pract Oncol Radiother 20(4):284–291CrossRef Buglione M, Ghirardelli P, Triggiani L, Pedretti S, Pasinetti N, de Bari B, Tonoli S, Borghetti P, Spiazzi L, Magrini SM (2015) Radiotherapy for adult medulloblastoma: long term result from a single institution. A review of prognostic factors and why we do need a multi-institutional cooperative program. Rep Pract Oncol Radiother 20(4):284–291CrossRef

go back to reference Balducci M, Chiesa S, Chieffo D et al (2012) The role of radiotherapy in adult medulloblastoma: long-term single-institution experience and a review of the literature. J Neuro-Oncol 106(2):315–323CrossRef Balducci M, Chiesa S, Chieffo D et al (2012) The role of radiotherapy in adult medulloblastoma: long-term single-institution experience and a review of the literature. J Neuro-Oncol 106(2):315–323CrossRef

go back to reference Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AAN, Giannini C, Li KKW, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DCY, Seow WT, Chang KTE, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fèvre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobágyi T, Klekner A, László B, Pócza T, Hauser P, Schüller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen MLC, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, López-Aguilar E, Lyden D, Garzia L, Shih DJH, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DTW, Chan JA, Nikolic A, Garre ML, van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD (2016) Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol 17(4):484–495CrossRef Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AAN, Giannini C, Li KKW, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DCY, Seow WT, Chang KTE, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fèvre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobágyi T, Klekner A, László B, Pócza T, Hauser P, Schüller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen MLC, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, López-Aguilar E, Lyden D, Garzia L, Shih DJH, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DTW, Chan JA, Nikolic A, Garre ML, van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD (2016) Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol 17(4):484–495CrossRef

go back to reference Bland JM (1998) Survival probabilities (the Kaplan-Meier method). BMJ 317(7172):1572–1580CrossRef Bland JM (1998) Survival probabilities (the Kaplan-Meier method). BMJ 317(7172):1572–1580CrossRef

go back to reference Majd N, Penas-Prado M et al (2019) Updates on management of adult medulloblastoma. Curr Treat Options in Oncol 20(8):64CrossRef Majd N, Penas-Prado M et al (2019) Updates on management of adult medulloblastoma. Curr Treat Options in Oncol 20(8):64CrossRef

go back to reference Atalar B, Ozsahin M, Call J, Napieralska A, Kamer S, Villa S, Erpolat P, Negretti L, Lassen-Ramshad Y, Onal C, Akyurek S, Ugurluer G, Baumert BG, Servagi-Vernat S, Miller RC, Ozyar E, Sio TT (2018) Treatment outcome and prognostic factors for adult patients with medulloblastoma: the Rare Cancer Network (RCN) experience. Radiother Oncol 127(1):96–102CrossRef Atalar B, Ozsahin M, Call J, Napieralska A, Kamer S, Villa S, Erpolat P, Negretti L, Lassen-Ramshad Y, Onal C, Akyurek S, Ugurluer G, Baumert BG, Servagi-Vernat S, Miller RC, Ozyar E, Sio TT (2018) Treatment outcome and prognostic factors for adult patients with medulloblastoma: the Rare Cancer Network (RCN) experience. Radiother Oncol 127(1):96–102CrossRef

go back to reference Franceschi E, Hofer S, Brandes AA, Frappaz D, Kortmann RD, Bromberg J, Dangouloff-Ros V, Boddaert N, Hattingen E, Wiestler B, Clifford SC, Figarella-Branger D, Giangaspero F, Haberler C, Pietsch T, Pajtler KW, Pfister SM, Guzman R, Stummer W, Combs SE, Seidel C, Beier D, McCabe MG, Grotzer M, Laigle-Donadey F, Stücklin ASG, Idbaih A, Preusser M, van den Bent M, Weller M, Hau P (2019) EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of postpubertal and adult patients with medulloblastoma. Lancet Oncol 20(12):e715–ee72CrossRef Franceschi E, Hofer S, Brandes AA, Frappaz D, Kortmann RD, Bromberg J, Dangouloff-Ros V, Boddaert N, Hattingen E, Wiestler B, Clifford SC, Figarella-Branger D, Giangaspero F, Haberler C, Pietsch T, Pajtler KW, Pfister SM, Guzman R, Stummer W, Combs SE, Seidel C, Beier D, McCabe MG, Grotzer M, Laigle-Donadey F, Stücklin ASG, Idbaih A, Preusser M, van den Bent M, Weller M, Hau P (2019) EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of postpubertal and adult patients with medulloblastoma. Lancet Oncol 20(12):e715–ee72CrossRef

go back to reference Cosman R, Brown CS, DeBraganca KC et al (2014) Patterns of care in adult medulloblastoma: results of an international online survey. J Neuro-Oncol 120(1):125–129CrossRef Cosman R, Brown CS, DeBraganca KC et al (2014) Patterns of care in adult medulloblastoma: results of an international online survey. J Neuro-Oncol 120(1):125–129CrossRef

go back to reference Trinh VT, Davies JM, Berger MS et al (2015) Surgery for primary supratentorial brain tumors in the United States, 2000-2009: effect of provider and hospital caseload on complication rates. Neurosurg. 122(2):280–296CrossRef Trinh VT, Davies JM, Berger MS et al (2015) Surgery for primary supratentorial brain tumors in the United States, 2000-2009: effect of provider and hospital caseload on complication rates. Neurosurg. 122(2):280–296CrossRef

go back to reference Long DM, Gordon T, Bowman H et al (2003) Outcome and cost of craniotomy performed to treat tumors in regional academic referral centers. Long DM Neurosurg 52(5):1056–1063 Long DM, Gordon T, Bowman H et al (2003) Outcome and cost of craniotomy performed to treat tumors in regional academic referral centers. Long DM Neurosurg 52(5):1056–1063

go back to reference De B, Beal K, De Braganca KC et al (2018) Long-term outcomes of adult medulloblastoma patients treated with radiotherapy. J Neuro-Oncol 136(1):95–104CrossRef De B, Beal K, De Braganca KC et al (2018) Long-term outcomes of adult medulloblastoma patients treated with radiotherapy. J Neuro-Oncol 136(1):95–104CrossRef

go back to reference Abacioglu U, Uzel O, Sengoz M, Turkan S, Ober A (2002) Medulloblastoma in adults: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys 54(3):855–860CrossRef Abacioglu U, Uzel O, Sengoz M, Turkan S, Ober A (2002) Medulloblastoma in adults: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys 54(3):855–860CrossRef

go back to reference Franceschi E, Bartolotti M, Paccapelo A, Marucci G, Agati R, Volpin L, Danieli D, Ghimenton C, Gardiman MP, Sturiale C, Poggi R, Mascarin M, Balestrini D, Masotto B, Brandes AA (2016) Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients? J Neuro-Oncol 128(2):235–240CrossRef Franceschi E, Bartolotti M, Paccapelo A, Marucci G, Agati R, Volpin L, Danieli D, Ghimenton C, Gardiman MP, Sturiale C, Poggi R, Mascarin M, Balestrini D, Masotto B, Brandes AA (2016) Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients? J Neuro-Oncol 128(2):235–240CrossRef

go back to reference Beier D, Proescholdt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs SE, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann RD, Bogdahn U, Hau P (2018) Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro-Oncology 20(3):400–410CrossRef Beier D, Proescholdt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs SE, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann RD, Bogdahn U, Hau P (2018) Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro-Oncology 20(3):400–410CrossRef

go back to reference Padovani L, Sunyach MP, Perol D et al (2007) Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys 68(2):433–440CrossRef Padovani L, Sunyach MP, Perol D et al (2007) Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys 68(2):433–440CrossRef

go back to reference Kann BH, Lester-Coll NH, Park HS et al (2017) Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-Oncology 19(2):259–269PubMed Kann BH, Lester-Coll NH, Park HS et al (2017) Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-Oncology 19(2):259–269PubMed

go back to reference Northcott PA, Buchhalter I, Morrissy AS et al (2017) The whole-genome landscape of medulloblastoma subtypes. Nature 547(7663):311–317CrossRef Northcott PA, Buchhalter I, Morrissy AS et al (2017) The whole-genome landscape of medulloblastoma subtypes. Nature 547(7663):311–317CrossRef

go back to reference Liu X, Ding C, Tan W, Zhang A (2020) Medulloblastoma: molecular understanding, treatment evolution, and new developments. Pharmacol Ther 210:107516. https://doi.org/10.1016/j.pharmthera.2020.107516CrossRefPubMed Liu X, Ding C, Tan W, Zhang A (2020) Medulloblastoma: molecular understanding, treatment evolution, and new developments. Pharmacol Ther 210:107516. https://​doi.​org/​10.​1016/​j.​pharmthera.​2020.​107516CrossRefPubMed

go back to reference Friedrich C, von Bueren AO, von Hoff K, Kwiecien R, Pietsch T, Warmuth-Metz M, Hau P, Deinlein F, Kuehl J, Kortmann RD, Rutkowski S (2013) Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study. Eur J Cancer 49:893–903CrossRef Friedrich C, von Bueren AO, von Hoff K, Kwiecien R, Pietsch T, Warmuth-Metz M, Hau P, Deinlein F, Kuehl J, Kortmann RD, Rutkowski S (2013) Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study. Eur J Cancer 49:893–903CrossRef